BioSpace News Archive

ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503/TJ-L14B in the Journal for ImmunoTherapy of Cancer(JITC).

Median Technologies, announces the publication date for its 2021 half year results and its Q3, 2021 business performance :

- Three-year overall allograft survival was 84% in crossmatch positive patients treated with imlifidase - In patients with a cPRA of ≥99.9%, three-year allograft survival was 92% - Data published in an article accepted by the American Journal of Transplantation

Ortho Clinical Diagnostics, one of the world’s largest pure-play in vitro diagnostics companies, announced its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test is the first quantitative COVID-19 IgG antibody test to receive U.S. Food and Drug Administration Emergency Use Authorization.

Perspectum is pleased to announce that a new prospective, observational, cohort study called Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing is underway.

Genetic Technologies Limited today announced updates on the development of its Predictive Panel Risk Test designed to cover six different cancers including breast and colorectal cancer, prostate and ovarian cancer, pancreatic cancer and melanoma.

I-Mab today announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.

VistaGen Therapeutics today announced that management will participate in the ‘Updates in Neuropsych’ panel at the virtual William Blair Biotech Focus Conference 2021 on July 15, 2021 at 9:00 a.m.

All existing inventory processed by Lattice Biologics Inc., or under private label, is safe to use until the expiration date and remains in full compliance with all regulatory bodies.

Bayer announced the U.S. FDA has approved KERENDIA®, a first-in-class nonsteroidal mineralocorticoid receptor antagonist indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes.